Clinical benefit with ripretinib as ≥fourth-line treatment in patients with advanced gastrointestinal stromal tumor: Update from the phase 3 INVICTUS study. 

Ripretinib Intra-Patient Dose Escalation Following Disease Progression Provides Clinically Meaningful Progression-Free Survival in Gastrointestinal Stromal Tumor in Phase 1 Study. 

Characterization of the extensive heterogeneity of KIT/PDGFRA mutations in patients with fourth-line advanced gastrointestinal stromal tumor: Genomic analysis of the phase 3 INVICTUS study.

Ripretinib demonstrated activity across all KIT/PDGFRA mutations in patients with fourth-line advanced gastrointestinal stromal tumor: Analysis from the phase 3 INVICTUS study. 

Phase 1 Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DCC-3014 in Advanced Solid Tumors and Tenosynovial Giant Cell Tumor (TGCT) (NCT3069469).